StoryFunding
Tune Therapeutics completes $175M Series B funding round
Tune Therapeutics raised $175M in Series B funding led by New Enterprise Associates, Yosemite, Regeneron Ventures, and Hevolution Foundation to advance its hepatitis B program TUNE-401 into clinical trials and expand its epigenome editing pipeline.
- Series B round totaled over $175 million, led by four major investors.
- Funding supports advancement of TUNE-401 into later-stage clinical development.
- Tune plans to expand its epigenome editing platform to additional disease areas.